Copyright ©ERS Journals Ltd 2007 Herpes simplex virus and atopy in Finnish and Russian Karelian children1 Skin and Allergy Hospital, Helsinki University Central Hospital, and 2 Dept of Chronic Diseases and Health Promotion, National Public Health Institute, Helsinki, Finland. To the Editors: Although the focus in the context of the hygiene hypothesis in explaining raised atopy prevalences has largely shifted from pathogens to commensals and saprophytes, the role of pathogens cannot be wholly ignored. Many pathogens are able to establish persistent or chronic infections, and have evolved strategies for immune evasion. A common immune subversion strategy used by such pathogens involves the increased production of the regulatory cytokines interleukin (IL)-10 and/or transforming growth factor-ß by innate immune cells or via the generation of regulatory T (T-reg)-cells 1. These cytokines, by inhibiting/downregulating the function of antigen-presenting cells and effector T-cells, appear, in turn, to be crucial for the development of tolerance against allergens.
We assessed whether seropositivities to three pathogens known to readily establish persistent/chronic infections (Helicobacter pylori, Toxoplasma gondii, herpes simplex virus (HSV)) and to hepatitis A virus (HAV; previously implicated in conferring protection against allergy) are associated with reduced risk of atopy. Schoolchildren aged 7–16 yrs were randomly recruited in Finnish (n = 344; mean age 11.3 yrs) and Russian Karelia (n = 425; mean age 11.5 yrs), two adjacent areas with contrasting lifestyles and high and low burden of atopic diseases, respectively. Atopy was defined as one or more positive (
Overall, 49% of children in Finland were atopic, compared with 20% in Russia (p<0.001). Approximately 26% of the children in Russia showed antibodies to T. gondii, 76% to HSV, 66% to H. pylori and 12% to HAV. In Finland, seropositivity rates were considerably lower and ranged from 3% (T. gondii) and 4% (HAV) to 7% (H. pylori), with the exception of HSV, which showed a seropositivity rate of 15%. When seropositivities were stratified according to the atopy status of the children, a significantly higher rate of seropositivity to HSV was found among nonatopics in Finland but not in Russia. No other differences between atopics and nonatopics in either country were found (table 1
HSV is interesting from the perspective of tolerance and allergy. HSV infection leads to lifelong viral latency with the potential for subsequent reactivations. T-reg cells that produce IL-10 and suppress the function of CD4+ and CD8+ effector T-cells have been shown to be generated in HSV infection in vivo 3. HSV has a glycoprotein-rich envelope that interacts with Toll-like receptor (TLR)2, and a double-stranded DNA genome rich in guanine and cytosine motifs interacting with TLR9 4. Ligation of both TLR2 and 9 on human cells has been shown to be associated with the development of T-reg cells and/or tolerance 5, 6. We found that HSV infection conferred protection against atopy among Finnish children only. Besides the fact that atopy is infrequent in Russian Karelia, the overall exposure to microorganisms is overwhelming and the impact of saprophytes and other pathogens may well override the possible effects of HSV on the Russian side. In summary, in an area with a relatively low microbial burden such as Finnish Karelia, herpes simplex virus appears to be able to exert immunomodulatory potential, which may have implications for the occurrence of atopy. This finding confirms the result shown previously in two other Western populations 7, 8. Statement of interest This study was funded by grants from the Helsinki University Central Hospital and the Allergy Foundation (both Helsinki, Finland).
ACKNOWLEDGEMENTS The members of the Karelian Allergy Study Group also include: P. Jousilahti and E. Vartiainen (National Public Health Institute, Helsinki); and T.U. Kosunen (Helsinki University/Haartman Institute, Helsinki, Finland). SUPPORT STATEMENT This study was founded by a Helsinki University Central Hospital (Helsinki Finland) grant and a grant from the Allergy Foundation. REFERENCES
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||